Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Antiviral Activity of Biktarvy in HIV-1 Infected Adolescents and Children
NCT02881320Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Sep 2016; status: active, not recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02881320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881320.